STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #309 by analyst upside · 2026-09-09
PRQR
ProQR Therapeutics N.V.
Healthcare · Market Cap $289M · P/E 0x
ANALYST PRICE TARGET
+301.1%
implied upside to consensus target
Current Price $2.05
Consensus Target $8.22
Bull Target $12.0
Bear Target $3.0
Analysts Covering 9
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
8
Hold
0
Sell
0
52-Week Low $1.33
52-Week High $3.1
YTD Return +3.0%
FUNDAMENTALS
Market Cap $289M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.46
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $18M
Profit Margin -228.2%
52-WEEK RANGE
52-Week Low $1.33
52-Week High $3.1
Current Price $2.05
Bear Target $3.0
Bull Target $12.0
● Now $2.05 ● Target $8.22
TRADING DATA
Avg Volume 1.1M
YTD Return +3.0%
Analyst Count 9
Consensus Buy
Upside to Target +301.1%
Last Updated 2026-09-09

ANALYST SUMMARY

ProQR Therapeutics N.V. (PRQR) is currently trading at $2.05 with a Wall Street consensus price target of $8.22, implying potential upside of 301.1% over the next 12 months. 9 analysts currently cover PRQR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $3.0.

PRQR operates in the Healthcare sector with a market capitalisation of $289M. The stock is up 3.0% year-to-date and is currently trading near the lower end of its 52-week range of $1.33 – $3.1.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRQR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

B of A Securities ● Initiated
Buy 2026-08-20 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-06-29 Building track record
Jones Trading - Reiterated
Buy → Buy 2026-06-26 57% win rate (14 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-06-26 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-04-09 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-11-04 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2025-08-08 33% win rate (6 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-06-27 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →